Unlike childhood acute lymphoblastic leukemia (ALL), there are currently no approved CAR T-cell products for the treatment of adult ALL; here, Noelle Frey, MD, from the University of Pennsylvania, Philadelphia, PA, explains how clinical trials investigating ALL are often scarce and extremely competitive to enroll patients. Dr Frey also shares her excitement about the future of CAR T-cell therapies and the benefits that will follow. This interview was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
